GALACTIC-HF, STRENGTH among late-breaking trials to be presented at virtual AHA meeting
Click Here to Manage Email Alerts
Research in HF, omega-3 fatty acids, cardiac imaging among women and drug-eluting stents are among the topics of late-breaking clinical trials being presented at the virtual American Heart Association Scientific Sessions.
The sessions will be held from Nov. 13 to Nov. 17.
The GALACTIC-HF pivotal trial, slated for presentation during the first late-breaker session, evaluated the effects of omecamtiv mecarbil (Amgen/Cytokinetics), a selective cardiac myosin activator, on reducing adverse cardiac outcomes in chronic HF with reduced ejection fraction.
Also in HF research, investigators will present findings from the AFFIRM-AHF trial, which assessed the use of ferric carboxymaltose in patients with an iron deficiency admitted to the hospital with acute HF.
New data in omega-3s include the STRENGTH trial, which assessed CV outcomes among patients with atherogenic dyslipidemia and at high vascular risk who received omega-3 carboxylic acids (Epanova, AstraZeneca), and VITAL Rhythm trial, which evaluated combination omega-3 fatty acid vitamin D supplementation for the prevention of atrial fibrillation. Healio previously reported in January that AstraZeneca stopped the STRENGTH trial for futility.
Findings from Women’s Heart Attack Research Program (HARP) will also be presented. The researchers assessed coronary OCT and cardiac MRI for identifying underlying causes of MI with no obstructive CAD (MINOCA) among women.
Two presentations from the TIPS-3 polypill study will be featured, one assessing a polypill for CVD prevention in intermediate-risk people and one comparing the polypill plus aspirin with aspirin alone for primary prevention.
Also being presented is the One-Month DAPT trial of aspirin monotherapy after 1 month of dual antiplatelet therapy following PCI with a DES.
Some other trials presented during the late-breaking sessions will shed light on trends in patient characteristics and CV outcomes in COVID-19 infection. In addition, the INVESTED trial of CV outcomes with high-dose vs. low-dose influenza vaccines will be presented.
Cardiology Today and Healio will be reporting news from the virtual AHA Scientific Sessions. Stay tuned for news, perspectives and more. Also follow @CardiologyToday on Twitter for continuing updates.
Click Here to Manage Email Alerts